Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) announced participation in two investor fireside chats in February 2026. The company will present at Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 at 9:00 a.m. ET and at Oppenheimer Virtual Healthcare Life Sciences on Feb 26, 2026 at 2:00 p.m. ET.

Live webcasts and archived replays will be available in the Investors section of the company website under “News and Events.”

News Market Reaction – KYMR

+0.62%

1 alert

+0.62% News Effect

On the day this news was published, KYMR gained 0.62%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Investor conferences: 2 events Guggenheim presentation time: 9:00 a.m. ET Oppenheimer presentation time: 2:00 p.m. ET

3 metrics

Investor conferences 2 events February 2026 conferences (Guggenheim, Oppenheimer)

Guggenheim presentation time 9:00 a.m. ET February 11, 2026 Guggenheim Emerging Outlook: Biotech Summit

Oppenheimer presentation time 2:00 p.m. ET February 26, 2026 Oppenheimer Virtual 36th Annual Healthcare Life Sciences Conference

Market Reality Check

Price: $83.52 Vol: Volume 648,227 is slightl...

normal vol

$83.52 Last Close

Volume Volume 648,227 is slightly below 20-day average 710,333 ahead of conference appearances. normal

Technical Shares at $77.22 trade above 200-day MA $53.30 and 25.03% below 52-week high $103.00, well above the 52-week low $19.445.

Peers on Argus

KYMR is up 2.12% while close biotech peers show mixed moves: APLS +3.64%, CRNX +...

KYMR is up 2.12% while close biotech peers show mixed moves: APLS +3.64%, CRNX +1.24%, SRRK +2.85%, versus declines in MLTX -3.33% and ZLAB -1.56%, pointing to stock-specific strength rather than a uniform sector move.

Historical Context

5 past events · Latest: Jan 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 29	Clinical trial update	Positive	+3.9%	First patient dosed in BREADTH Phase 2b asthma trial for KT-621.
Jan 13	Strategy update	Positive	+1.4%	Outlined 2026 objectives and reported ~$1.6B cash runway into 2029.
Jan 06	Conference presentation	Neutral	+1.4%	Announcement of presentation at 44th Annual J.P. Morgan Healthcare Conference.
Dec 11	Equity offering	Negative	-2.3%	Closing of upsized public offering with ~$692.3M in gross proceeds.
Dec 11	Regulatory designation	Positive	-2.3%	FDA Fast Track designation for KT-621 in atopic dermatitis.

Pattern Detected

Recent clinical and strategy updates have generally seen positive price reactions, while a Fast Track designation previously coincided with a short-term pullback.

Recent Company History

Over the past few months, Kymera has reported several key milestones. A Dec 11, 2025 Fast Track designation for KT-621 and a subsequent Jan 29, 2026 first-patient dosing in the BREADTH Phase 2b asthma trial both underscored pipeline momentum. A large upsized equity offering on Dec 11, 2025 raised substantial capital but coincided with a negative price reaction. Strategy and conference communications in January 2026 were associated with modest gains, framing today’s conference-focused news as part of an ongoing investor-engagement cadence.

Market Pulse Summary

This announcement highlights Kymera’s continued engagement with the investment community through Feb...

Analysis

This announcement highlights Kymera’s continued engagement with the investment community through February conferences, providing venues to update on its clinical pipeline and strategy. Recent history includes major milestones such as the KT-621 Fast Track designation on Dec 11, 2025, a substantial equity raise the same day, and first-patient dosing in the BREADTH trial on Jan 29, 2026. Investors may watch for any new clinical timelines, capital plans, or portfolio priorities shared during these events.

Key Terms

fireside chats, webcasts

2 terms

fireside chats financial

"the Company will participate in fireside chats at the following upcoming investor events"

An informal, conversational presentation—often led by a CEO or executive and sometimes including a question-and-answer segment—used to update investors and the public on a company’s strategy, performance and outlook. Like a town-hall chat around a fireplace, it reveals leadership tone, confidence and transparency; investors watch these talks for insights that can clarify management’s priorities, reduce uncertainty and sometimes move share prices.

webcasts technical

"Live webcasts of the presentations will be available under “News and Events”"

Webcasts are live or recorded audio and video broadcasts delivered over the internet, often used for earnings calls, investor presentations, and corporate announcements. They let investors see and hear company leaders directly—like watching a live TV show or listening to a podcast—so you can assess tone, get extra detail beyond written reports, and hear answers to questions in real time; that direct access can influence how investors value a company.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events: 

• Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY on February 11 at 9:00 a.m. ET; and
• Oppenheimer Virtual 36^th Annual Healthcare Life Sciences Conference on February 26 at 2:00 p.m. ET.

Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events. 

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn. 

Investor and Media Contact: 
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300 

FAQ

When will Kymera Therapeutics (KYMR) present at the Guggenheim Biotech Summit in 2026?

Kymera will present at the Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 at 9:00 a.m. ET. According to the company, this fireside chat will be held in New York and available via live webcast on its investor site.

How can investors watch Kymera Therapeutics (KYMR) at the Oppenheimer conference on Feb 26, 2026?

Investors can watch Kymera’s Oppenheimer presentation on Feb 26, 2026 at 2:00 p.m. ET via live webcast. According to the company, the webcast is available under News and Events in the Investors section of its website.

Will Kymera Therapeutics (KYMR) provide replays of its February 2026 investor presentations?

Yes. Kymera will archive and make replays available after each event on its investor website. According to the company, archived webcasts will be accessible under the News and Events section for on-demand viewing.

What topics will Kymera Therapeutics (KYMR) likely cover during the February 2026 fireside chats?

The company will discuss its clinical-stage programs and degrader medicines for immunological diseases during the fireside chats. According to the company, presentations will focus on recent development updates and corporate strategy for investors.

Where is the official webcast for Kymera Therapeutics (KYMR) investor events hosted?

The official webcasts are hosted on Kymera’s investor website under the News and Events section. According to the company, both live streams and archived replays will be posted there for investor access.